HomeME • NASDAQ
23andMe Holding Co.
$0.46
After Hours:
$0.47
(1.19%)+0.0055
Closed: Apr 26, 8:00:00 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$0.46
Day range
$0.45 - $0.48
Year range
$0.35 - $2.21
Market cap
223.63M USD
Avg Volume
7.21M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
44.75M-33.15%
Operating expense
100.85M-14.34%
Net income
-277.98M-202.28%
Net profit margin
-621.22-352.19%
Earnings per share
EBITDA
-75.46M4.25%
Effective tax rate
-0.01%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
242.42M-43.99%
Total assets
608.21M-40.64%
Total liabilities
231.02M-15.58%
Total equity
377.19M
Shares outstanding
482.92M
Price to book
0.59
Return on assets
-28.70%
Return on capital
-34.81%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-277.98M-202.28%
Cash from operations
-12.06M-147.21%
Cash from investing
-2.01M34.38%
Cash from financing
105.00K1,054.55%
Net change in cash
-13.97M-164.34%
Free cash flow
-2.60M-104.31%
About
23andMe Holding Co. is a publicly trading personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell. The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. In 2007, 23andMe became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008. Wikipedia
Founded
Apr 2006
Employees
758
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu